初诊急性髓系白血病患者接受维奈克拉联合阿扎胞苷治疗伴或不伴抗真菌预防时真菌感染频率
该观察性研究分析了捷克、奥地利和斯洛伐克血液中心初诊接受维奈克拉联合阿扎胞苷一线治疗的急性髓系白血病患者中,接受与未接受抗真菌预防队列的真菌感染频率。186例患者中85例(46%)接受抗真菌预防,101例(54%)未接受预防;真菌感染在预防组为1/85(1%),未预防组为5/101(5%)(p=0.222)。两队列死亡率(p=0.296)和总生存(p=0.844)无显著差异。
要点
- 186例初诊AML患者中46%接受抗真菌预防,54%未接受预防。
- 真菌感染发生率预防组1%(1/85) vs 未预防组5%(5/101),p=0.222。
- 两队列死亡率和总生存无显著差异,多数感染不严重且发生于第一治疗周期。
核心结论
- 多数感染不严重,发生于第一治疗周期,且未影响患者总体结局。
研究设计与样本
- 观察性研究,分析捷克、奥地利和斯洛伐克血液中心初诊接受维奈克拉联合阿扎胞苷一线治疗的急性髓系白血病患者。
- 共纳入186例患者,85例(46%)接受抗真菌预防,101例(54%)未接受预防。
主要发现
- 真菌感染发生于预防组1/85例(1%) vs 未预防组5/101例(5%)(p=0.222)。
- 两队列死亡率无显著差异(p=0.296)。
- 两队列总生存无显著差异(p=0.844)。
- 多数感染不严重,发生于第一治疗周期,且未影响患者总体结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
引用
- Weinbergerová B, Mayer J, Kabut T, et al. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis. Br J Haematol. 2024. PMID: 39044120. doi:10.1111/bjh.19670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。